Program · Outcome 1: Better equip Australia to meet current and future health needs of all Australians through the delivery of evidence-based health policies; improved access to comprehensive and coordinated health care; ensuring sustainable funding for health services, research and technologies; and protecting the health and safety of the Australian community
Program 1.1: Health Research, Coordination and Access
Fund Australian health and medical research, blood fractionation and blood related products.
Department of Health, Disability and Ageing, 2026-27 Portfolio Budget Statements, PDF page 66 reported
+$411m (+16.7%) on 2025-26 estimated actual
Traced to named suppliers and grant recipients
AusTender and GrantConnect record the agency, not the program, so contracts and grants are shown on the entity page.
Published lines
Each row is one line of the program’s expense table in the 2026-27 Portfolio Budget Statements – Program Expense Line Items, as published.
| Line | Kind | 2025-26 estimated actual |
2026-27 Budget estimate |
Change | Treatment | Source |
|---|---|---|---|---|---|---|
| National Health Act 1953 - blood fractionation products and blood related products to National Blood Authority | administered | $1.3bn | $1.5bn | +$248m +19.3% | reported | 2.1.1 Outcome 1, row 693 |
| Medical Research Future Fund | administered | $650m | $650m | no change 0.0% | reported | 2.1.1 Outcome 1, row 692 |
| Payments to corporate entities | administered | $360m | $411m | +$51m +14.2% | reported | 2.1.1 Outcome 1, row 695 |
| Ordinary annual services | administered | $162m | $274m | +$112m +69.2% | reported | 2.1.1 Outcome 1, row 689 |
| Services for Other Entities and Trust Moneys Special Account | administered | $12m | $13m | +$603k +5.0% | reported | 2.1.1 Outcome 1, row 691 |
| Public Governance, Performance and Accountability Act 2013 s77 - repayments | administered | $2.0m | $2.0m | no change 0.0% | reported | 2.1.1 Outcome 1, row 694 |
| to Services for Other Entities and Trust Moneys Special Account | administered | −$12m | −$13m | −$603k – | reported | 2.1.1 Outcome 1, row 690 |